UMIN-CTR Clinical Trial

Unique ID issued by UMIN UMIN000005877
Receipt number R000006858
Scientific Title Randomised Phase II study of combined Docetaxel and Nedaplatin versus Docetaxel alone chemotherapy in advanced or recurrent esophageal cancer
Date of disclosure of the study information 2011/07/01
Last modified on 2020/01/06 14:53:11

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

Randomised Phase II study of combined Docetaxel and Nedaplatin versus Docetaxel alone chemotherapy in advanced or recurrent esophageal cancer

Acronym

ECDN

Scientific Title

Randomised Phase II study of combined Docetaxel and Nedaplatin versus Docetaxel alone chemotherapy in advanced or recurrent esophageal cancer

Scientific Title:Acronym

ECDN

Region

Japan


Condition

Condition

Advanced or recurrent esophageal cancer

Classification by specialty

Gastrointestinal surgery

Classification by malignancy

Malignancy

Genomic information

NO


Objectives

Narrative objectives1

Efficacy

Basic objectives2

Safety

Basic objectives -Others


Trial characteristics_1

Confirmatory

Trial characteristics_2

Pragmatic

Developmental phase

Phase II


Assessment

Primary outcomes

Overall survival

Key secondary outcomes

overall survival, one year survival rate, progression free survival, objective response rate, adverse events


Base

Study type

Interventional


Study design

Basic design

Parallel

Randomization

Randomized

Randomization unit

Cluster

Blinding

Open -no one is blinded

Control

Active

Stratification


Dynamic allocation


Institution consideration


Blocking


Concealment



Intervention

No. of arms

2

Purpose of intervention

Treatment

Type of intervention

Medicine

Interventions/Control_1

NDP(80mg/m2) and DOC(60mg/m2) combination chemotherapy

Interventions/Control_2

DOC (70mg/m2) chemotherapy

Interventions/Control_3


Interventions/Control_4


Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit

20 years-old <=

Age-upper limit

80 years-old >=

Gender

Male and Female

Key inclusion criteria

1.recurreent esophageal cancer
2.the tumor has a measurable lesion for evaluation.
3.5FU/CDDP resistance
4.ECOG PS:0 to 2
5.Age from 20 to 80 years
6.Adequate organ function
WBC:>3,000/ mm3 <12,000/mm3
Neutro:>1,500/mm3
Hb:>9.0 g/dl
Plt:>100,000/mm3
T-Bil:<1.5mg / dl
AST(GOT),ALT(GPT):within 2.5 times the normal upper limits
Ccr: 1.5mg/dl
C.Cr:>50ml / min (Cockcroft- Gault)
7. Written informed consent

Key exclusion criteria

(1) patient who has drug allergy as past history
1. Known hypersensitivity to DOC, NDP and Polysorbate-80
2. patient who has active infectious disease
3. patient who has active double cancer
4. patient who has severe complication (interstitial pneumonitis, DM etc.)
5.concomitant treatment with steroids
6.EDEMA
7. patient who want to be pregnant and /or pregnant woman
8. patient who was judged to be unsuitable for this clinical trial

Target sample size

43


Research contact person

Name of lead principal investigator

1st name Hideaki
Middle name
Last name Shimada

Organization

Toho University School of Medicine

Division name

Department of Surgery

Zip code

181-0001

Address

6-11-1 Omori-Nishi, Ota-ku, Tokyo

TEL

0422577669

Email

yajiman68@yahoo.co.jp


Public contact

Name of contact person

1st name Satoshi
Middle name
Last name Yajima

Organization

Division of General and Gastroenterological Surgery, Department of Surgery (Omori), Toho University

Division name

Department of Surgery

Zip code

143-8541

Address

6-11-1 Omori-nishi Ota-ku Tokyo Japan

TEL

0422577669

Homepage URL


Email

yajiman68@yahoo.co.jp


Sponsor or person

Institute

Toho University

Institute

Department

Personal name



Funding Source

Organization

None

Organization

Division

Category of Funding Organization

Self funding

Nationality of Funding Organization



Other related organizations

Co-sponsor


Name of secondary funder(s)



IRB Contact (For public release)

Organization

Toho Unoversity School of Medicine

Address

6-11-1 Omori-nishi Ota-ku Tokyo Japan

Tel

0337624151

Email

yajiman68@yahoo.co.jp


Secondary IDs

Secondary IDs

NO

Study ID_1


Org. issuing International ID_1


Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions



Other administrative information

Date of disclosure of the study information

2011 Year 07 Month 01 Day


Related information

URL releasing protocol


Publication of results

Unpublished


Result

URL related to results and publications


Number of participants that the trial has enrolled


Results


Results date posted


Results Delayed


Results Delay Reason


Date of the first journal publication of results


Baseline Characteristics


Participant flow


Adverse events


Outcome measures


Plan to share IPD


IPD sharing Plan description



Progress

Recruitment status

Completed

Date of protocol fixation

2011 Year 05 Month 16 Day

Date of IRB

2011 Year 05 Month 19 Day

Anticipated trial start date

2011 Year 07 Month 01 Day

Last follow-up date

2018 Year 03 Month 31 Day

Date of closure to data entry

2018 Year 08 Month 31 Day

Date trial data considered complete

2019 Year 03 Month 31 Day

Date analysis concluded

2019 Year 03 Month 31 Day


Other

Other related information



Management information

Registered date

2011 Year 06 Month 29 Day

Last modified on

2020 Year 01 Month 06 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000006858


Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name